Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid - 2A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- 3Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- 4Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- 574 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
- Flu cases spiking this holiday season, CDC data shows
- Select Your Go-To Bluetooth Earphones
- The German series proving subtitles can be sexy — and wildly addictive
- Beating Wellbeing Difficulties: Individual Victories in Health
- Courageous Climbing: Trails and Stuff for Outside Lovers
- 5 Christmas movies to stream for less with this Paramount+ Black Friday deal
- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
